AI-designed protein switch uses caffeine to pause engineered cell activity

Caffeine can act as a signal for specially engineered cells, not just as a familiar stimulant. Texas A&M researchers used AI-assisted protein design to build CODS, a system that separates connected proteins when caffeine is present. Published on May 25, 2026, the work remains a laboratory demonstration rather than an available treatment.

Using caffeine to control cells has a history. ETH Zurich researchers tested caffeine-responsive gene switches in diabetic mice in 2018. Earlier COSMO research also brought engineered proteins together in response to caffeine. CODS reverses the arrangement: the signal breaks an interaction instead of forming one.

Imagine two people who must hold hands to carry out a shared task. Releasing their hands changes what they can do together. The biological effect depends on the engineered task attached to that interaction. Ordinary cells have not been equipped with this particular control system, so drinking coffee does not provide arbitrary control over a person's genes.

AI helped design small binding proteins. Researchers then evaluated and refined candidates computationally and tested them in living cells. Of 13 initial candidates, one showed clear binding in the cellular assay before further optimization. The experimental work, rather than a computer prediction alone, established the useful behavior.

Demonstrations included controlling gene activity. The immune-cell experiment used the laboratory Jurkat cell line, not treatment in patients. This direction is relevant to CAR-T cells, which are modified to recognize cancer but can cause serious side effects when excessively active. The team's ambition is an adjustable pause rather than permanently eliminating those therapeutic cells.

The everyday significance is a potential way to make cell therapies more controllable, not a new health benefit of coffee. Further work in therapeutic cells, animals and disease settings is still needed. Caffeine is the experimental signal here, not a substitute for cancer treatment.

Original paper published: May 25, 2026.